Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jviromet.2021.114084 http://scihub22266oqcxt.onion/10.1016/j.jviromet.2021.114084 33513380!7837211!33513380     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Virol+Methods 2021 ; 290 (ä): 114084 Nephropedia Template TP {{tp|p=33513380|t=2021. Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants |pdf=|usr=}}{{33513380}} gab.com Text Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants JO: J Virol Methods http://www.kidney.de/pget.php?&tw=1&pmid=33513380 #FOAvip The use of monoclonal neutralizing antibodies (mNAbs) is being actively pursued as a viable intervention for the treatment of Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) infection and associated coronavirus disease 2019 (COVID-19). While highly potent mNAbs have great therapeutic potential, the ability of the virus to mutate and escape recognition and neutralization of mNAbs represents a potential problem in their use for the therapeutic management of SARS-CoV-2. Studies investigating natural or mNAb-induced antigenic variability in the receptor binding domain (RBD) of SARS-CoV-2 Spike (S) glycoprotein, and their effects on viral fitness are still rudimentary. In this manuscript we described experimental approaches for the selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants (MARMs) in cultured cells. The ability to study SARS-CoV-2 antigenic drift under selective immune pressure by mNAbs is important for the optimal implementation of mNAbs for the therapeutic management of COVID-19. This will help to identify essential amino acid residues in the viral S glycoprotein required for mNAb-mediated inhibition of viral infection, to predict potential natural drift variants that could emerge upon implementation of therapeutic mNAbs, as well as vaccine prophylactic treatments for SARS-CoV-2 infection. Additionally, it will also enable the assessment of MARM viral fitness and its potential to induce severe infection and associated COVID-19 disease. Twit Text FOAVip Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants ????J Virol Methods http://www.kidney.de/pget.php?&tw=1&pmid=33513380 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33513380 #FOAvip English Wikipedia <ref>{{Cite pmid|33513380}}</ref> Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants #MMPMID33513380 Oladunni FS; Park JG; Chiem K; Ye C; Pipenbrink M; Walter MR; Kobie J; Martinez-Sobrido L J Virol Methods 2021[Apr]; 290 (ä): 114084 PMID33513380show ga The use of monoclonal neutralizing antibodies (mNAbs) is being actively pursued as a viable intervention for the treatment of Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) infection and associated coronavirus disease 2019 (COVID-19). While highly potent mNAbs have great therapeutic potential, the ability of the virus to mutate and escape recognition and neutralization of mNAbs represents a potential problem in their use for the therapeutic management of SARS-CoV-2. Studies investigating natural or mNAb-induced antigenic variability in the receptor binding domain (RBD) of SARS-CoV-2 Spike (S) glycoprotein, and their effects on viral fitness are still rudimentary. In this manuscript we described experimental approaches for the selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants (MARMs) in cultured cells. The ability to study SARS-CoV-2 antigenic drift under selective immune pressure by mNAbs is important for the optimal implementation of mNAbs for the therapeutic management of COVID-19. This will help to identify essential amino acid residues in the viral S glycoprotein required for mNAb-mediated inhibition of viral infection, to predict potential natural drift variants that could emerge upon implementation of therapeutic mNAbs, as well as vaccine prophylactic treatments for SARS-CoV-2 infection. Additionally, it will also enable the assessment of MARM viral fitness and its potential to induce severe infection and associated COVID-19 disease. |*Selection, Genetic[MESH] |Animals[MESH] |Antibodies, Monoclonal/immunology/*pharmacology/therapeutic use[MESH] |Antibodies, Neutralizing/immunology/pharmacology/therapeutic use[MESH] |Antigenic Variation/*genetics[MESH] |Binding Sites/genetics/immunology[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/virology[MESH] |Chlorocebus aethiops[MESH] |Drug Resistance, Viral/*genetics[MESH] |Humans[MESH] |Phenotype[MESH] |SARS-CoV-2/drug effects/*genetics/immunology[MESH] |Spike Glycoprotein, Coronavirus/genetics/immunology[MESH]Selection, identification, and characterization of SARS-CoV-2 monoclon(epmc).pdf DeepDyve Pubget Overpricing